Catalyst Pharma Files 8-K on Material Agreement; Details Pending

TL;DR

**Catalyst Pharma filed an 8-K about a material agreement, but gave no details, leaving investors guessing.**

AI Summary

On January 4, 2024, Catalyst Pharmaceuticals, Inc. filed an 8-K to report an "Entry into a Material Definitive Agreement" and "Regulation FD Disclosure." While the filing indicates a significant event, it does not provide specific details about the agreement itself, such as names, dollar amounts, or the nature of the transaction. This lack of detail means investors are currently in the dark about the specifics of this material agreement, which could impact the company's future prospects and stock value.

Why It Matters

This filing signals a significant corporate event for Catalyst Pharmaceuticals, Inc., but without specific details, investors cannot assess its potential impact on the company's financial health or strategic direction.

Risk Assessment

Risk Level: medium — The filing indicates a material event without providing specifics, creating uncertainty and potential for significant market reaction once details are disclosed.

Analyst Insight

A smart investor would monitor Catalyst Pharmaceuticals, Inc. for subsequent filings or press releases that provide specific details about the 'Material Definitive Agreement' before making any investment decisions, as the current filing lacks actionable information.

Key Players & Entities

• CATALYST PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
• January 4, 2024 (date) — date of the earliest event reported
• Delaware (company) — state of incorporation for Catalyst Pharmaceuticals, Inc.
• 001-33057 (dollar_amount) — Commission File Number for Catalyst Pharmaceuticals, Inc.
• 355 Alhambra Circle, Suite 801, Coral Gables, Florida, 33134 (company) — address of principal executive offices for Catalyst Pharmaceuticals, Inc.

Forward-Looking Statements

• Catalyst Pharmaceuticals, Inc. will file an amendment or a subsequent 8-K with more details about the material definitive agreement. (CATALYST PHARMACEUTICALS, INC.) — high confidence, target: 2024-02-04
• The stock price of Catalyst Pharmaceuticals, Inc. may experience volatility upon the release of specific details regarding the material definitive agreement. (CATALYST PHARMACEUTICALS, INC.) — medium confidence, target: 2024-03-04

FAQ

From the Filing

0001193125-24-003489.txt : 20240105 0001193125-24-003489.hdr.sgml : 20240105 20240105172331 ACCESSION NUMBER: 0001193125-24-003489 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240104 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240105 DATE AS OF CHANGE: 20240105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 24517565 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d149661d8k.htm 8-K 8-K NASDAQ false 0001369568 0001369568 2024-01-04 2024-01-04     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 4, 2024     CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter)       Delaware   001-33057   76-0837053 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)     355 Alhambra Circle   Suite 801   Coral Gables , Florida   33134 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (305) 420-3200 Not Applicable Former Name or Former address, if changed since last report     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Name of Exchange on Which Registered   Ticker Symbol Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company   ☐                  If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐       Item 1.01 Entry into a Material Definitive Agreement On January 4, 2024, Catalyst Pharmaceuticals, Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) wi